PRINCETON, NJ and MENLO PARK, CA, Jul 24, 2013 (Marketwired via COMTEX) — Corcept Therapeutics Incorporated CORT announced today that Korlym(R) (mifepristone) 300 mg Tablets is available to patients outside of the United States through an Idis Access Program.
Idis Access Programs enable patients around the world to be prescribed investigational or approved drugs prior to their commercial launch in that country through a regulatory-compliant and ethical channel on a named-patient basis. Corcept, a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders, has been offering Korlym in the United States since April 2012 as a once-daily oral treatment of hyperglycemia secondary to endogenous Cushing’s syndrome in adult patients who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
“We are pleased to partner with Idis so that physicians outside the United States can prescribe Korlym,” said Steven Lo, Corcept’s Vice President of Commercial Operations. “We are dedicated to meeting the needs of patients worldwide. Our partnership with Idis will help us make sure that every Cushing’s syndrome patient who could benefit from Korlym will have access to the medicine.”
Charles Simmons, President of Established Brands at Idis said of the partnership, “We are very excited to work with Corcept to provide patients around the world with access to this important treatment. Patients are at the heart of what we do at Idis and providing access to an important medicine like Korlym, creating a bridge to treatment irrespective of the number of patients involved, is one of the ways we do it”.
Licensed healthcare professionals outside the United States with patients who might benefit from Korlym should contact Idis directly:
Idis UK & Eire Enquiries Tel: +44 (0) 1932 824 100 Fax: +44 (0) 1932 824 300 Email: uk@idispharma.com
Idis Rest of the World Enquiries Tel: +44 (0) 1932 824 123 Fax: +44 (0) 1932 824 323 Email: internationalsales@idispharma.com
About Cushings Syndrome Endogenous Cushing’s syndrome is caused by prolonged exposure of the body’s tissues to high levels of the hormone cortisol and is generated by tumors that produce cortisol or ACTH. Cushing’s syndrome is an orphan indication that most commonly affects adults aged 20 to 50. Symptoms vary, but most people have one or more of the following manifestations: high blood sugar, diabetes, high blood pressure, upper body obesity, rounded face, increased fat around the neck, thinning arms and legs, severe fatigue and weak muscles. Irritability, anxiety, cognitive disturbances and depression are also common. Cushing’s syndrome can affect every organ system in the body and can be fatal if not treated effectively.
About Corcept Therapeutics Incorporated Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders. Korlym, a first generation GR-II antagonist, is the company’s first FDA-approved medication. Corcept has a phase 3 trial underway for mifepristone for treatment of the psychotic features of psychotic depression and a portfolio of selective GR-II antagonists that block the effects of cortisol but not progesterone. It owns extensive intellectual property covering the use of GR-II antagonists, including mifepristone, in the treatment of a wide variety of metabolic and psychiatric disorders. It also holds composition of matter patents for its selective GR-II antagonists. For more information about Corcept please visit: http://www.corcept.com
About Idis Idis has 25 years experience partnering with pharmaceutical and biotechnology companies to create regulatory-compliant, ethical access to medicines for healthcare professionals and their patients with unmet medical needs. Since 1987, Idis has developed and managed access to thousands of medicines from every therapeutic category, impacting the lives of hundreds of thousands of patients in countries around the world.
Idis leverages decades of experience, regulatory insight, and a thorough understanding of local and global requirements to create access to medicines at every stage of a product’s lifecycle from pre-approval to market exit, and in times of unexpected production shortages.
The company’s European headquarters are located in Weybridge, United Kingdom, and North American headquarters are located in Princeton, NJ.
For more information about Idis please visit http://www.idispharma.com.
From Marketwatch
Like this:
Like Loading...
Filed under: Cushing's, pituitary, Treatments | Tagged: Adrenocorticotropic hormone, COMTEX, Corcept, Cushing, Cushing Syndrome, drugs, Idis, Idis Access Programs, Korlym, Steven Lo, United States | Leave a comment »
CushieBlog 